Original BioMedicals Co., Ltd.
Original BioMedicals Co., Ltd., engages in the development of new drugs with non-new ingredients in Taiwan. It develops OBM-A01, for the treatment of acute radiation injury, including nuclear radiation and solar radiation exposed in space; OBM-B01, a cyanide compound drug for protection against toxic gases from fires; and CCM-CL, a cyclic polypeptide antibiotic. The company was founded in 2011 an… Read more
Original BioMedicals Co., Ltd. - Asset Resilience Ratio
Original BioMedicals Co., Ltd. (6483) has an Asset Resilience Ratio of 38.46% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how Original BioMedicals Co., Ltd.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Original BioMedicals Co., Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$89.83 Million | 38.46% |
| Total Liquid Assets | NT$89.83 Million | 38.46% |
Asset Resilience Insights
- Very High Liquidity: Original BioMedicals Co., Ltd. maintains exceptional liquid asset reserves at 38.46% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Original BioMedicals Co., Ltd. Industry Peers by Asset Resilience Ratio
Compare Original BioMedicals Co., Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Original BioMedicals Co., Ltd. (2021–2024)
The table below shows the annual Asset Resilience Ratio data for Original BioMedicals Co., Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 32.12% | NT$89.74 Million | NT$279.37 Million | +5.20pp |
| 2023-12-31 | 26.93% | NT$99.80 Million | NT$370.63 Million | -8.70pp |
| 2022-12-31 | 35.63% | NT$34.93 Million | NT$98.04 Million | -18.86pp |
| 2021-12-31 | 54.49% | NT$74.85 Million | NT$137.37 Million | -- |